These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

306 related articles for article (PubMed ID: 36060954)

  • 1. The role of protein kinase C in diabetic microvascular complications.
    Pan D; Xu L; Guo M
    Front Endocrinol (Lausanne); 2022; 13():973058. PubMed ID: 36060954
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The role of protein kinase C activation and the vascular complications of diabetes.
    Das Evcimen N; King GL
    Pharmacol Res; 2007 Jun; 55(6):498-510. PubMed ID: 17574431
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inhibition of protein kinase C β ameliorates impaired angiogenesis in type I diabetic mice complicating myocardial infarction.
    Ikeda A; Matsushita S; Sakakibara Y
    Circ J; 2012; 76(4):943-9. PubMed ID: 22313801
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Diabetes causes bone marrow endothelial barrier dysfunction by activation of the RhoA-Rho-associated kinase signaling pathway.
    Mangialardi G; Katare R; Oikawa A; Meloni M; Reni C; Emanueli C; Madeddu P
    Arterioscler Thromb Vasc Biol; 2013 Mar; 33(3):555-64. PubMed ID: 23307872
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Activation of protein kinase C isoforms and its impact on diabetic complications.
    Geraldes P; King GL
    Circ Res; 2010 Apr; 106(8):1319-31. PubMed ID: 20431074
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Molecular complexities underlying the vascular complications of diabetes mellitus - A comprehensive review.
    Paul S; Ali A; Katare R
    J Diabetes Complications; 2020 Aug; 34(8):107613. PubMed ID: 32505477
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Molecular targets of diabetic cardiovascular complications.
    Ahmad FK; He Z; King GL
    Curr Drug Targets; 2005 Jun; 6(4):487-94. PubMed ID: 16026267
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Early microvascular complications of prediabetes in mice with impaired glucose tolerance and dyslipidemia.
    Schaefer C; Biermann T; Schroeder M; Fuhrhop I; Niemeier A; Rüther W; Algenstaedt P; Hansen-Algenstaedt N
    Acta Diabetol; 2010 Dec; 47 Suppl 1():19-27. PubMed ID: 19367364
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Diabetic microangiopathy: Pathogenetic insights and novel therapeutic approaches.
    Madonna R; Balistreri CR; Geng YJ; De Caterina R
    Vascul Pharmacol; 2017 Mar; 90():1-7. PubMed ID: 28137665
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PKC inhibition and diabetic microvascular complications.
    Clarke M; Dodson PM
    Best Pract Res Clin Endocrinol Metab; 2007 Dec; 21(4):573-86. PubMed ID: 18054736
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Protein kinase C-beta inhibition and diabetic microangiopathy: effects on endothelial permeability responses in vitro.
    Idris I; Gray S; Donnelly R
    Eur J Pharmacol; 2004 Feb; 485(1-3):141-4. PubMed ID: 14757134
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-like peptide-1 protects against cardiac microvascular injury in diabetes via a cAMP/PKA/Rho-dependent mechanism.
    Wang D; Luo P; Wang Y; Li W; Wang C; Sun D; Zhang R; Su T; Ma X; Zeng C; Wang H; Ren J; Cao F
    Diabetes; 2013 May; 62(5):1697-708. PubMed ID: 23364453
    [TBL] [Abstract][Full Text] [Related]  

  • 13. PKC-B inhibition: a new therapeutic approach for diabetic complications?
    Avignon A; Sultan A
    Diabetes Metab; 2006 Jun; 32(3):205-13. PubMed ID: 16799396
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Ruboxistaurin, a protein kinase C beta inhibitor, as an emerging treatment for diabetes microvascular complications.
    Joy SV; Scates AC; Bearelly S; Dar M; Taulien CA; Goebel JA; Cooney MJ
    Ann Pharmacother; 2005 Oct; 39(10):1693-9. PubMed ID: 16160002
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A PKC-beta inhibitor treatment reverses cardiac microvascular barrier dysfunction in diabetic rats.
    Wei L; Yin Z; Yuan Y; Hwang A; Lee A; Sun D; Li F; Di C; Zhang R; Cao F; Wang H
    Microvasc Res; 2010 Jul; 80(1):158-65. PubMed ID: 20079359
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Can C-peptide mediated anti-inflammatory effects retard the development of microvascular complications of type 1 diabetes?
    Luppi P; Kallas Å; Wahren J
    Diabetes Metab Res Rev; 2013 Jul; 29(5):357-62. PubMed ID: 23463541
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The role of protein kinase C activation in the pathogenesis of diabetic vascular complications.
    Park JY; Ha SW; King GL
    Perit Dial Int; 1999; 19 Suppl 2():S222-7. PubMed ID: 10406523
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Activation of protein kinase C by elevation of glucose concentration: proposal for a mechanism in the development of diabetic vascular complications.
    Lee TS; Saltsman KA; Ohashi H; King GL
    Proc Natl Acad Sci U S A; 1989 Jul; 86(13):5141-5. PubMed ID: 2740348
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A role for the endothelial glycocalyx in regulating microvascular permeability in diabetes mellitus.
    Perrin RM; Harper SJ; Bates DO
    Cell Biochem Biophys; 2007; 49(2):65-72. PubMed ID: 17906361
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Proatherosclerotic mechanisms involving protein kinase C in diabetes and insulin resistance.
    Rask-Madsen C; King GL
    Arterioscler Thromb Vasc Biol; 2005 Mar; 25(3):487-96. PubMed ID: 15637306
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 16.